Revenue: As of FY2026 Q1, the actual value is USD 51.18 M.EPS: As of FY2026 Q1, the actual value is USD -1.65.EBIT: As of FY2026 Q1, the actual value is USD -33.93 M.<h3>Segment Revenue</h3><ul><li>Net Sales: $51.2 million for the quarter ended June 30, 2025, a decrease of 22.7% from $66.2 million for the same period in 2024.</li><li>Reorder Sales: $41.3 million, down 21.8% from $52.8 million in 2024.</li><li>New Order Sales: $8.2 million, down 25.6% from $11.1 million in 2024.</li><li>Membership Fees: $1.6 million, down 29.9% from $2.3 million in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $14.4 million, a decrease of 24.3% from $19.0 million in 2024.</li><li>Gross Margin: 28.1%, down from 28.8% in 2024.</li><li>Operating Expenses: $48.5 million, up from $14.7 million in 2024, primarily due to a $27.3 million impairment of goodwill and intangible assets.</li><li>Net Loss: - $34.2 million, compared to a net income of $3.8 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $12.3 million for the three months ended June 30, 2025, compared to - $8.5 million in 2024.</li><li>Net Cash Used in Investing Activities: - $1.3 million, compared to - $0.7 million in 2024.</li><li>Net Cash Used in Financing Activities: - $30 thousand, compared to - $0.1 million in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Adjusted EBITDA: - $2.7 million, compared to - $1.5 million in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on improving operational efficiency and aligning staffing needs to better support current and expected future levels of operations.</li><li>Non-Core Business: The company received unsolicited acquisition proposals, which are under review by the Board to determine the best course of action for shareholders.</li></ul>

Petmed Express | 10-Q: FY2026 Q1 Revenue: USD 51.18 M